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Resumo
Estima-se que, atualmente, cerca 67 milho˜es de pessoas em todo o mundo
sofram de glaucoma, doenc¸a esta que pode levar a` cegueira quando na˜o
tratada. Os tratamentos dispon´ıveis no mercado possuem efeitos secunda´rios
adversos e/ou necessitam de destreza manual por parte do paciente para
serem administrados corretamente. Nesta perspectiva, e de forma a melho-
rar a biodisponibilidade do fa´rmaco no olho atrave´s da administrac¸a˜o de uma
dose mais baixa de medicamento, diversos tipos de sistemas de libertac¸a˜o teˆm
vindo a ser desenvolvidos.
Devido essencialmente a` sua elevada biocompatibilidade e interesse para
aplicac¸o˜es biome´dicas, o poli(a´cido la´ctico) (PLA) foi o pol´ımero escolhido
para o desenvolvimento deste trabalho. Contudo, sendo um material duro e
quebradic¸o, a sua utilizac¸a˜o em diversas aplicac¸o˜es tem sido limitada. Por
forma a viabilizar a sua utilizac¸a˜o na aplicac¸a˜o final, o uso de plastificantes
tem-se mostrado como uma promissora alternativa. Assim, o presente tra-
balho tem como finalidade o estudo do PLA como material pass´ıvel de ser uti-
lizado na entrega de fa´rmacos anti glaucoma. Para tal, numa primeira etapa,
procedeu-se a` s´ıntese e caracterizac¸a˜o de polie´steres saturados (SP) para plas-
tificac¸a˜o do PLA e, utilizando os filmes de PLA desenvolvidos, estudou-se
numa segunda fase a capacidade de libertac¸a˜o controlada de fa´rmaco anti
glaucoma dos mesmos.
Diferentes polie´steres saturados foram sintetizados por policondensac¸a˜o
utilizando, para tal, diferentes glico´is e a´cidos saturados. Apo´s sintetizados,
os diversos SPs foram caracterizados qu´ımica, te´rmica e morfologicamente.
Atrave´s das referidas ana´lises verificou-se, com sucesso, a obtenc¸a˜o de quatro
polie´steres: dois alifa´ticos (SP1 e SP3) e dois aroma´ticos (SP2 e SP4). De
ix
xseguida, por solvent casting, procedeu-se a` formac¸a˜o de filmes de PLA com
polie´steres, utilizando o clorofo´rmio como solvente. Para a obtenc¸a˜o do filme
final, o solvente utilizado na sua preparac¸a˜o foi evaporado numa estufa a
50 oC. Atrave´s deste me´todo todos os polie´steres mostraram ser capazes
de formar filmes com o PLA. Contudo, apenas os polie´steres SP1 e SP3
mostraram ser capazes de formar filmes com o PLA e cujas propriedades
mecaˆnicas os tornam pass´ıveis de ser estudados para libertac¸a˜o controlada
de fa´rmaco. Apo´s caracterizac¸a˜o, os filmes com melhores propriedades -
SP1 PLA50 (formulac¸a˜o SP1/PLA na proporc¸a˜o de 50/50), SP3 PLA70
(formulac¸a˜o SP3/PLA na proporc¸a˜o de 30/70) e SP3 PLA50 (formulac¸a˜o
SP3/PLA na proporc¸a˜o de 50/50) - foram revestidos com a soluc¸a˜o polime´rica
de origem (PLA com SP) ou com um silicone reativo. Posteriormente foram
realizados estudos de libertac¸a˜o de acetazolamida, um fa´rmaco anti glau-
coma. O filme SP3 PLA70, formulac¸a˜o de PLA com polie´ster de a´cido
seba´cico e 1,6-hexanodiol, provou ser o mais promissor dos treˆs no que se
refere aos perfis de libertac¸a˜o do fa´rmaco. No que respeita aos revestimen-
tos estudados, ambos mostraram ser eficazes na diminuic¸a˜o da libertac¸a˜o do
fa´rmaco. Paralelamente, e numa ana´lise comparativa, o mesmo processo de
secagem foi realizado a` temperatura ambiente, avaliando assim o impacto da
evaporac¸a˜o lenta do clorofo´rmio sendo obtidos os mesmos resultados quando
em comparac¸a˜o com a evaporac¸a˜o na estufa.
Abstract
Currently, about 67 million people worldwide are affected by glaucoma.
Without an appropriate treatment this disease can lead to irreversible blind-
ness. The treatments available in the market present adverse side effects
and/or require manual dexterity of the patient to be administered properly.
In this regard, and in order to improve the bioavailability of the drug in the
eye, a variety of drug delivery systems have been developed. Poly(lactic acid)
(PLA) was chosen for the development of this work due to its high biocom-
patibility and interest for biomedical applications. However, this polymer is
a brittle and stiff material, which restricts its use in a variety of applications,
namely ocular drug delivery systems. The use of plasticizers aims to improve
the mechanical properties in order to meet the specifications of the final ap-
plication. Thus, the present work aims to study the PLA as a material that
can be used in the delivery of anti glaucoma drugs. To this end, in a first
stage, different saturated polyesters (SP) were synthesized and character-
ized in order to plasticize PLA. In a second stage, the developed SP/PLA
films were studied by their ability for controlled release of acetazolamide, an
anti-glaucoma drug.
Different saturated polyesters were synthesized by polycondensation using
different saturated glycols and acids. Once synthesized, the different SPs
have been characterized chemically, thermally and morphologically. Through
these analyzes, it was verified that four polyesters, two aliphatic (SP1 and
SP3) and two aromatic (SP2 and SP4), were successfully obtained. Then,
using chloroform as solvent, the formation of SP/PLA films was performed by
solvent casting. To obtain the final films, the solvent used in their preparation
was evaporated in an oven at 50 oC. All the polyesters showed to be able
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to form films with PLA. However, only SP1 and SP3 polyesters showed to
be able to form films with the PLA with mechanical properties of interest
for drug controlled release. After characterization, the films with improved
properties - SP1 PLA50 (films containing 50/50 wt.% of SP1/PLA), SP3
PLA70 (films containing 30/70 wt.% of SP3/PLA) and SP3 PLA50 (films
containing 50/50 wt.% of SP3/PLA) - were coated with the film main solution
(SP PLA) or with a silicone.
Afterwards, acetazolamide release studies were performed. The SP3 PLA70
films proved to be the most promising of the three films used in this study,
in what concerns the drug release profiles. As regards the studied coatings,
both showed to be effective in lowering drug release. At the same time, the
same drying process was performed at room temperature in order to evaluate
the impact of slow evaporation of the chloroform in the film properties. The
obtained results were similar to those obtained for the film prepared in the
oven at 50 oC.
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Introduction
Currently, it is estimated that 67 million people worldwide suffer from glau-
coma. If left untreated glaucoma can lead to irreversible blindness. The
available medications are effective for a majority of cases but the treatments
in the market have side effects and/or require manual dexterity to be admin-
istered correctly. [1] In this regard, and in order to improve the compliance
of the treatment and the bioavailability of the drug in the eye, different types
of controlled drug release systems have been developed.
Poly(lactic acid) is a synthetic polymer obtained from renewable sources,
highly biocompatible and a promising material to biomedical applications,
particularly drug delivery systems. However, this polymer is brittle and stiff
which restricts its use in ocular drug delivery systems. The use of plasticizers
aims to improve these properties in order to meet the specifications of the
final application. [2]
Thus, the main goal of this work is the study of biocompatible materials
for delivery of anti-glaucoma drugs. PLA was chosen for this work. Different
polyesters were synthesized and characterized, for the plasticization of PLA.
The mechanical properties of the resulting film were studied and the most
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promising films were chosen. Acetazolamide was encapsulated within the
films and the controlled release of the drug was studied.
2
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State of Art
2.1 Glaucoma
According to World Health Organization (WHO), glaucoma is an optic neu-
ropathy determined by both structural changes and functional deficit. [3] In
this disease, a specific type of retinal cells (the ganglion cells) die and, conse-
quently, the connection between the eye and brain is progressively compro-
mised. [1][4] Thus, with a damage in the optic nerve, an increasing of intra
ocular pressure (IOP) is currently observed. The first symptom of glaucoma
is the lost of peripheral vision and, then, a reduction in the central vision.
The main cause of glaucoma is related to the individual, depending on age
and genetic predisposition, being extremely difficult to prevent. [1][3] With-
out appropriate treatment, glaucoma leads to irreversible blindness. It is
estimated that 67 million people worldwide are currently affected by glau-
coma. For instance, up to 80 % of the world’s blindness can be avoided and
different initiatives have been carried out in this area. [1]
There are 2 major subtypes of glaucoma, open-angle and angle-closure
glaucoma, characterized based on the status of the internal drainage system
3
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of the eye. In both cases, high IOP has a tremendous responsibility in the
progression of the disease but, alone, it is not enough for the diagnostic of
glaucoma. IOP is the only modifiable risk factor that can avoid the progres-
sion of the disease and, therefore, different studies have been carried out over
the years to develop a new medical therapy to prevent high IOP values. [1]
Commonly, IOP increases when the formation of aqueous humor is higher
than the draining ability through the internal outflow system (see Figure 2.1).
The trabecular meshwork is the major component of the outflow system and,
in open-angle glaucoma, is the site of resistance to the draining of aqueous
humor, leading to a slow and painless loss of peripheral vision. On the
contrary, in angle-closure glaucoma, the trabecular meshwork is blocked by
the iris. This fact leads to a rapid increase of IOP, which causes pain and
sudden blurring of vision. [1]
Figure 2.1: Normal eye versus eye with glaucoma, reprinted from [5].
As a disease that affects millions of people worldwide, glaucoma treatment
is a major concern. Over the years different approaches have been studied
4
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in order to slow down the rate of glaucomatous damage and, consequently,
maintain adequate visual function. In the future, the early detection of the
disease will be one of the main goals and new IOP-lowering agents, new surgi-
cal techniques and devices and different ways of drug delivery will be carefully
developed. Specifically with drug delivery systems, the treatment compliance
will be enhanced and the patient’s dependence on self-administration will be
reduced.
2.1.1 Glaucoma - The treatment
Currently, the therapy for glaucoma is focused on decreasing IOP by medi-
cal, laser and/or surgical therapy. In early stages, this disease is frequently
treated with both medical and laser therapy. [1][3]
Medical therapy is based on daily administration of medication, usually
used in early stages of the disease and also applied to control the IOP after
surgery. However, glaucoma is difficult to diagnose and commonly affects old
aged people. These facts can affect the effectiveness of the medical therapy
which significantly depends on the treatment adherence. Another problem
of this therapy is the measurement of the treatment effectiveness. Different
patients have different reaction to therapy and, therefore, distinct degree of
IOP reduction. Therefore, it is important to develop new modes of drug
delivery to surpass the problems presented before. [1]
Laser therapy is often administered for the treatment of both open-angle
and angle-closure glaucoma. This type of therapy can be used at any moment
during the treatment and is frequently applied with medical therapy. Laser
therapy is also used in medication intolerant patients. In the treatment of
open-angle glaucoma, a laser is directed for the trabecular meshwork in order
to increase the outflow of aqueous humor and, consequently, lower the IOP
5
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in a process called trabeculoplasty. In angle-closure glaucoma, in a process
called laser iridotomy, the laser is used to create a microscopic opening in
the iris, allowing the outflow of aqueous humor. [1]
Finally, surgical therapy has proven to be a highly effective method to
lower IOP as an alternative to medical and/or laser therapy. In the proce-
dure, known as trabeculectomy, the aqueous humor is drained from the eye
to the subconjunctival space and, consequently, the IOP is reduced. In a
situation in which the eye has previous scarring and/or has been subjected
to other surgeries a synthetic device, such as a tube shunt, is implanted to
allow the flow of the aqueous humor to a reservoir. [1]
Over the years many drugs have been studied to reduce IOP by decreasing
the aqueous humor in the eye. β-blockers and carbonic anhydrase inhibitors
are specific inhibitors applied to decrease the aqueous humor formation. On
the other hand, prostaglandin is applied to increase the outflow of aqueous
humor and, consequently, also reduces the IOP. [1][6] Acetazolamide is an
example of a carbonic anhydrase inhibitor used to treat glaucoma. This drug,
commercially known as Diamox R©, is currently the most effective drug to
lower IOP and avoid blindness. [6][7] In the eye, carbonic anhydrase inhibitor
prevents the action of the carbonic anhydrase enzyme (CA), responsible for
the reversible catalysis of H2O and CO2 to form hydrogencarbonate (HCO
−
3 )
and hydrogen ion (H+) (see Equation 2.1). [6]
H2O + CO2
CA↔ H+ +HCO−3 (2.1)
The presence of HCO−3 ion causes the movement of Na
+ and water into
the eye. If this reaction does not occur, the water will not be able to move into
the posterior chamber of the eye and form aqueous humor. Consequently,
with low aqueous humor formation, lower IOP will be attained. [6]
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Many other carbonic anhydrase inhibitors were studied over the years
such as dorzolamide, also known as Trusopt R©. [7][8] When comparing these
two drugs, Maus and co-workers [8] concluded that acetazolamide is more
efficient than dorzolamide in reducing aqueous humor flow. However, the
first can have side effects, especially in long-term treatments such as diuresis
and metabolic acidosis. [6][7]
Different efforts have been made to develop a topical preparation of ac-
etazolamide. Indeed, some problems related with this drug have emerged
due to its poor penetration coefficient and poor solubility in water. These
facts lead to a limited ocular penetration of the drug and, consequently, in-
sufficient amount of acetazolamide reaching the ciliary body. Despite the
limitations presented by acetazolamide, this drug is still used for the treat-
ment of acute glaucoma and post-surgical control of IOP. Acetazolamide is a
well-established drug in the treatment of glaucoma, which makes it a cheap
treatment. Furthermore, it reduces effectively the IOP without interfering in
the outflow system of aqueous humor. [6][7]
Over the years different approaches have been studied in order to over-
come the problems associated with topical and oral glaucoma medications.
For instance, oral medication, such as acetazolamide, has very low bioavail-
ability in the eye and presents significant side effects. [6][7] On the other
hand, topical medication used to treat glaucoma such as dorzolamide and
timolol maleate, present some problems related with administration, compli-
ance and also side effects. [8][9]
In an effort to surpass the limitations indicated above, controlled drug
delivery systems (DDS) have been studied over the years. A DDS is “a for-
mulation or a device that enables the introduction of a therapeutic substance
in the body and improves its efficacy and safety by controlling the rate, time,
7
Chapter 2
and place of release of drugs in the body”. [10] The use of DDS allows the use
of smaller amounts of therapeutic drug, which makes them more economic
when compared to the commercial available solutions. [11][12]
Currently, there are already some DDS developed for the treatment of
eye diseases. Retisert R©, Medidur R© and Vitrasert R© are polymeric DDS that
have been used for long-term drug delivery in posterior segment of the eye.
These approaches were studied for eye diseases, but not glaucoma. [9][12]
Timoptic-XE R© and Nyogel R© are gel forming solutions, consisting of water
soluble polymers that, when in the eye, increase the drug retention when
compared to eye drops. [9][13] Other approaches have been studied such as
liposomes, nanospheres and ocular inserts. It should be noted that the ocular
inserts proved to be effective in the delivery of pilocarpine, an anti-glaucoma
drug, for a period of 7 days. [9][12][13]
Nowadays, for the treatment of the glaucoma, the development of DDS
able to release a drug for several days or weeks have been presented as a
big challenge. With this purpose, implantable polymeric devices have been
studied in the last years. Wang and co-workers [14] developed poly(lactide-
co-glycolide) (PLGA) films in order to release ethacrynic acid (ECA) in the
eye, a potential anti-glaucoma drug. Through in vivo studies, the authors
found that the films were able to release the drug in a controlled manner,
being observed a decrease in the IOP values for at least 10 days. In an-
other work, Bertram and co-workers [15] developed microspheres of poly(D,L-
lactic-co-glycolic acid) and PLA to deliver timolol maleate (a β-adrenergic
receptor antagonist) in the subconjunctival of the eye. In their study, the
developed material showed a sustained release of the drug for approximately
3 months. This treatment was the longest sustained delivery of timolol
maleate described in the literature but its efficiency in lowering IOP was
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still undetermined. In 2009, Schultz and co-workers [16] incubated com-
mercial contact lenses in two different source solutions containing timolol
maleate and brimonide tartrate, respectively, and studied the release kinet-
ics. Three volunteers (with glaucoma and subjected to previous treatment)
used impregnated contact lenses for 30 minutes a day for 2 weeks. IOP was
maintained at levels equivalent to those obtained with other treatments. A
similar approach was taken by Costa and co-workers [17], who used commer-
cial silicone-based hydrogel contact lenses and impregnated them with two
drugs, acetazolamide and timolol maleate. This was achieved using a discon-
tinuous supercritical solvent impregnation (SSI) methodology. This method
was proven ineffective since the release of the medications was complete af-
ter 4 hours in sink conditions. More recently in 2011, Natu and co-workers
[12] prepared implantable films by blending poly(ε-caprolactone) (PCL) with
Lutrol F 127 (poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene
oxide)) and dorzolamide. The films were first prepared by solvent casting,
with acetone. Then a dip-coating process, with a PCL-solution, was carried
out in order to diminish the burst effect and improve the control the release
of the drug from the discs. With this approach, the IOP of normotensive
rabbits decreased by 13 % for a period of 10 days, for PCL-coated samples.
Since the previous preparation mode is not reproducible, a new preparation
method was developed by the same authors. [11] Melt compression proved to
be an effective method to develop the Lu/PCL discs with a small polymer-
to-drug ratio. The effect of PCL with different molecular weights was also
studied. For disks with low molecular weight PCL, the release was complete
after 1 month, as revealed by the in vivo experiments. On the other hand,
high molecular weight PCL showed non-cumulative releases rates above the
therapeutic level during 3 months in vivo, being a promising material. [11]
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Further investigation needs to be carried out in order to increase the de-
livery of a drug by DDS (6 months to 2 years), with a more efficient treatment
of glaucoma. As worth mentioning, polymeric materials such as poly(lactic-
co-glycolic acid), PCL, polyanhydride and poly(orthoesther) have been used
in the preparation of biodegradable implants to meet this objective. PLA is
currently a material with a huge potential for biomedical applications, being
a very promising material for biodegradable DDS. As mentioned above, PLA
was used in the preparation of films and microspheres to treat glaucoma.
But due to its inherent mechanical properties it has been copolymerized
with monomers and other polymers in order to improve its mechanical prop-
erties. [18] More detailed information about PLA properties and application
is presented next.
2.2 Poly(lactic acid)
Poly(lactic acid) or polylactide (PLA) is an extremely versatile and biodegrad-
able aliphatic polyester, which has received significant attention in the past
years. Obtained from a 100% renewable raw material, the lactic acid (LA),
PLA is indicated as a sustainable alternative to petrochemical-based mate-
rials. Currently, it is one of the most remarkable polyesters, being used in a
wide range of applications. [2][19][20][21]
PLA was firstly synthesized by Theo´phile-Jules Pelouze, in 1845, by con-
densation of lactic acid. However, the synthesis of this polymer only gained
interest in 1932 when Wallace Carothers polymerized lactide (a lactic acid
cyclic dimer) to obtain PLA, being the process patented later by DuPont.
Despite its promising properties, the use of PLA was initially limited for
many applications due to its high cost and low molecular weight. In the
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early 1990s, the breakthrough occurred when poly(L-lactide) (PLLA) with
high molecular weight was synthesized by ring opening polymerization (ROP)
of the lactide. Later, this polymer was commercialized by the same company,
Cargill Inc. In 1997, a joint venture formed by Cargill and the Dow Chemical
Company led to the emergence of the NatureWorks LLC, fully dedicated to
the production of PLA. Currently, NatureWorks LLC is the main supplier of
PLA, under the brand name IngeoTM, with a production capacity of 140 000
metric tons per year. [22][23]
In the last years, the main use of PLA was in food and food-related ap-
plications, such as candy wrap and packaging. However, due to its good
biocompatibility and, namely, due to its biodegradability PLA has presented
itself as a promising material in medical science, particularly in tissue engi-
neering and DDS. [20][21]
As mentioned before, PLA is obtained from the monomer lactic acid (or 2-
hydroxy propionic acid). LA is a chiral molecule, existing in two enantiomeric
forms: the L-lactic acid (LLA) and D-lactic acid (DLA) (see Figure 2.2). [24]
Figure 2.2: Chemical structure of lactic acid.
LA can be synthesized in two distinct pathways, by fermentation or by
chemical route. The carbon source needed for the fermentation process can
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be obtained from agriculture by-products such as sugarcane, potato, tapioca
and wheat, making this method financially attractive. Different bacterial
strains are used to obtain the two distinct forms (D(-) + L(+)) of LA. When
comparing the two methods, the fermentation process is presented as more
attractive due to the low energy and temperature required, low CO2 emissions
and, as indicated above, the low prices of substrate. Therefore, around 90%
of lactic acid is produced by bacterial fermentation to obtain a product with
high specificity. [2][19][21][24]
As indicated above, and being LA a chiral molecule, poly(lactic acid)
refers to a family of polymers: pure poly(L-lactic acid) (PLLA), pure poly(D-
lactic acid) (PDLA) and poly(D,L-lactic acid) (PDLLA). [2][20][21]
PLA is presently synthesized through two different methods: direct poly-
condensation of lactic acid and ROP of the lactide. The polycondensation of
LA occurs in bulk by removal of water of condensation by the use of vacuum
and temperature. Through this method, a low-molecular-weight polymer in
the range of 10 000 to 20 000 g.mol−1 is obtained. Thus, in order to increase
the molecular weight of the polymer external coupling agents such as iso-
cyanates, acid chlorides, anhydride and epoxides, are used. This constitutes
the least expensive route to produce PLA. On the other hand, ROP process
concerns three steps: polycondensation, depolymerization and ring opening
polymerization of lactide. Low molecular weight LA oligomers are synthe-
sized by polycondensation. This process is followed by depolymerization of
the LA oligomers in order to produce a cyclic dimer, the lactide. Finally,
PLA with controlled molecular weight is produced from the lactide by ring
opening polymerization. Both of these methods use catalysts to obtain PLA.
In direct polycondensation the catalysts used are boric and sulfuric acids,
whereas in ROP stannous octoate is the catalyst used. [2][19][21][25] In the
12
Chapter 2
future new and environmental friendly methods to produce PLA have to be
developed.
2.2.1 Properties
PLA is a quite attractive polymer and, due to its properties, can be found
on large-scale applications and also in biomedical and pharmaceutical indus-
tries. This polymer presents itself as a clear, colorless thermoplastic that can
be processed into fiber and films. However, PLA is also a brittle and stiff
material at room and body temperatures, presenting low ability to plastic
deformation. [2][19][25][26]
For many applications an important characteristic is the degradation rate
of the polymer. Degradation of polylactides, unlike most other biodegrad-
able polymers, occurs in two distinct steps. First, in a hydrolytic degradation
mechanism the scission of the ester groups occurs, with the consequent de-
crease of the molecular weight of the polymer. Only then, microorganisms
are able to metabolize the low molecular weight PLA chains into lactic acid.
In addition to temperature and moisture levels, crystallinity of the polymer
is a parameter that also determines the degradation time of PLA. Highly
crystalline polymer will take months or even years to degrade completely.
On the contrary, an amorphous polymer can degrade in weeks. [21][25]
The in vitro degradation of polylactides is dependent on the pH of the
solution. The in vitro degradation results can be used as a predictor of in
vivo degradation of the polymer. For instance, a phosphate-buffered solution
with pH of 7.4 at 37 oC can be used to mimic the conditions of the human eye
and to understand the PLA degradation mechanism. Tsuji and co-workers
[27] used these conditions to evaluate the degradation of PLLA. They found
out that the hydrolysis of PLA occurs mainly due to bulk erosion and in
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the amorphous areas of the polymer. The presence of enzymes can lead
to formation of pores and fragmentation of the polymer which increases its
degradation rate. [28]
In general, at room temperature, PLA is soluble in chloroform, dichloromethane,
acetonitrile, methylene chloride, 1,1,2-trichloroethane and dichloroacetic acid.
In contrast, solvents like ethyl benzene, toluene, acetone and tetrahydrofu-
ran are only able to completely dissolve PLA at the boiling temperature.
[2][21][25]
PLA can be easily processed by conventional techniques used for thermo-
plastics such as injection moulding and blow moulding extrusion. [26] How-
ever, for specific applications, PLA cannot compete with the conventional
polymers. For instance, it presents inferior thermal stability and impact
resistance to those of conventional thermoplastics. [2][25]
PLA is highly biocompatible and biodegradable polymer and, conse-
quently, it’s a promising material for biomedical applications. As mentioned
above, its stiffness and brittleness are its major drawbacks, especially in ap-
plications such as ocular drug delivery systems. In the last years, different
works have been carried out in order to change the properties of this poly-
mer. The use of plasticizers to improve the PLA properties will be discussed
below.
2.2.2 Plasticizers
Plasticizers have been used to improve the polymers processability, flexibility
and durability. [29][30] By definition, a plasticizer is a small organic molecule
that is added to a polymer in order to reduce its brittleness, improve its
flexibility and toughness, to reduce the crystallinity and lower the Tm and
Tg. Ideally, a plasticizer should be biodegradable, non-volatile and non-toxic,
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with minimal leaching and phase separation, during storage and end-use
applications. [30][31][32]
There are two types of plasticizers. Whereas internal plasticizers are
part of the polymer (a second polymer is copolymerized into the polymer
structure making the polymer chains more difficult to fit with each other),
the external plasticizers are low volatility molecules which, without chemical
reaction, interact with the polymer. [30]
In a plasticization of a polymer, the plasticizer increases the free volume
between the polymeric chains, decreasing the number of polymer-polymer in-
teractions. Thus, with lower Tg values, a polymer with lower rigidity and brit-
tleness and improved mechanical properties will be obtained. [30][31][33][34]
The effects of plasticizers in polymeric networks can be explained by three
theories. The lubricity theory states that the plasticizers act as lubricants,
contributing to an increase in the mobility of the polymeric chains. Accord-
ing to the gel theory, the plasticizer replaces polymer-polymer interactions
that keep the polymer together and, consequently, there is an increase in the
flexibility of the material. Finally, according to the free volume theory, the
plasticizer increases and preserves the free volume of the polymer (internal
space available for the movement of the polymeric chains) after processing.
This theory helps to explain the effect of plasticizers in Tg. [30]
Over the years, different plasticizers have been studied in order to find
an economical and easy method to modify PLA. Low molecular weight com-
pounds such as oligomeric lactic acid and low molecular weight citrates have
been used as plasticizers for PLA. [29][30][34] However, some of these plas-
ticizers can exhibit leaching during the use, thermal instability and biocom-
patibility issues. Thus, a common way to reduce migration and leaching
of plasticizers, during processing and storage, is to increase their molecular
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weight, without comprising the miscibility with PLA. In this respect, poly-
mers have been investigated as plasticizer for PLA. [32][35] For instance,
Martino and co-workers [36] studied the use of three commercial polyadi-
pates (Glyplast R©) as plasticizers to modify PLA, which showed to be able
to increase the elongation of the PLA and decrease its elastic modulus and
tensile stress. Recently, Lapol R© (polyester) has been introduced in the mar-
ket as a bioplasticizer for PLA. It is claimed to be an efficient plasticizer for
PLA at relative low concentrations (5-10 wt.%), promoting toughness and
flexibility while minimizing the reduction of Tg. [32][35]
In general, polymeric plasticizers are less efficient that monomeric ones
when it comes to improve elongation and reduce Tg of PLA. On the other
hand, they provide better stiffness-toughness balance for PLA and are less
prone to leaching. Thus, in order to obtain a polymer with improved prop-
erties and processing behavior for a specific application, an adequate choice
of plasticizer type must be made. [30]
2.2.3 Applications
PLA has shown huge potential to be used as a bioplastic in a wide range
of applications; packaging for food, in textile industry as disposable gar-
ments, feminine hygiene products, nappies, wipes and in medical care, and
in agriculture, such as films and matrix for controlled release of fertilizers
and herbicides. [21][25]
In recent years the use of PLA in biomedical fields, specifically in tis-
sue engineering, has been extensively growing. This fact, related with its
versatility, makes PLA a key material for biomedical applications. Some ex-
amples of its application in this so important area are degradable sutures,
drug delivery systems (DDS) and porous scaffolds. [19][20][25]
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Taking advantage of PLA characteristics, biodegradable implants have
been developed. Thus, after the reparation of a tissue, a second surgery
to remove the implant can be suppressed. In the last few years, PLA has
also been used to produce microspheres and microcapsules for DDS. These
devices are characterized by a controlled release of drugs over time. On the
other hand, and due to its slow degradation rate, PLLA has been used to
repair ligaments and tendons. In addition, due to its excellent mechanical
properties, this polymer has also been used in scaffolds, for cell growth, and
bone fixation devices. [21][25]
Nowadays, one challenge in the treatment of glaucoma is the development
of a device to deliver anti-glaucoma medication in the eye, in a controlled
manner.
Considering the indicated properties of PLA, namely its biocompatibility,
DDS can be developed for the treatment of glaucoma. As exposed earlier,
acetazolamide has side effects associated with its systemic administration,
such as diuresis and metabolic acidosis. The use of DDS for the adminis-
tration of this drug, allows the elimination of frequent dosing by the patient
and, consequently, better treatment compliance, fewer side effects and lower
doses. The main difficulty in the development of this type of DDS is, so far,
the correct plasticization of PLA.
For the purpose of this master thesis, polymeric blends will be devel-
oped in order to create a DDS with improved drug release properties for the
treatment of glaucoma. With this purpose, saturated polyesters will be syn-
thesized and used to plasticize PLA. Acetazolamide will be also encapsulated
within these structures and its release rate evaluated.
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Materials and Experimental
Methodology
3.1 Materials
Sebacic acid (SeA, ≥ 95%), diethylene glycol (DEG, 99%), 1,6-hexanediol
(HEX, 97%), isophthalic acid (IPhA, 99%), p-toluenesulfonic acid mono-
hydrate (98.5%), acetazolamide and phosphate buffered saline (PBS) were
purchased from Sigma-Aldrich (St. Louis, USA). Deuterated THF (THF-d8,
99.5%) was purchased from Eurisotop (France). Chloroform, dichloromethane
and tetrahydrofuran (THF) were supplied by Fisher Chemicals (United King-
dom). Potassium hydroxide solution (1N, in ethanol) was purchased from
Acros Organic (Geel, Belgium) and n-butyl acetate and ethanol (96%) were
supplied by Panreac (Spain). Phenolphthalein was obtained from Riedel-de-
Ha¨en (Germany). Poly-(lactic acid) IngeoTM 2500 HP was obtained from
Nature Works LLC (Blair, USA). Acetone was purchased from JMGS Lda.
(Odivelas, Portugal). All the reactants were used as received, unless other-
wise stated.
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3.2 Experimental Methodology
3.2.1 Synthesis of Saturated Polyesters
The saturated polyesters (SP1, SP2, SP3 and SP4) were prepared by bulk
polycondensation (Figure 3.1). The monomers (glycols and acids) and the
catalyst (p-toluenesulfonic acid monohydrate, 1 wt.%) were charged into the
four-necked glass reactor (1), equipped with a mechanical stirrer (2), a ni-
trogen inlet (3) and a condenser (4) connected to a round-bottom flask (5).
Figure 3.1: Illustration of a polycondensation reaction.
The polycondensations were carried out and water was distilled during
reaction. The end of reaction was set when the acid value (AV) reached a
value below 30 mg KOH/g (according to ASTM 109-01). Table 3.1 presents
the molar percentages of the different compounds in the feed formulations
and the synthesis conditions of the synthesized polyesters.
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Table 3.1: Reaction conditions of the SPs.
Polyester
Saturated Acids (%) Diols (%) Temperature
SeA IPhA DEG HEX 180oC 190oC 205oC
SP1 45,5 - 54,5 - 2h 4h 2h
SP2 22,5 22,5 55,0 - 2h 4h -
SP3 45,5 - - 54,5 2h 4h 2,75h
SP4 21,7 21,7 - 56,5 2h 4h -
Saturated polyester can be obtained by polycondensation of a saturated
acid and a diol. In this work, the synthesized SPs are based on SeA, a
biobased monomer. SP1 has SeA and DEG, a diol, in its constitution. The
use of DEG allows one to obtain linear saturated polyester with high flexibil-
ity. By its turn, SP2 has two saturated acids: SeA, as mentioned, and IPhA.
The last is used in order to grant rigidity to polymer chains. Finally, with
the purpose to study the influence of a diol with a long hydrocarbon chain,
SP3 and SP4 were prepared using HEX. Similar to SP2, SP4 has in its con-
stitution IPhA. The use of a catalyst (p-toluenesulfonic acid monohydrate)
was required in the polycondensations.
3.2.2 Plasticization of PLA and film formation
After the synthesis of saturated polyesters (SP), the obtained materials were
used to plasticize PLA, with the formation of films.
In order to improve the properties of PLA, blends of SP/PLA were pre-
pared using chloroform as the solvent. PLA and a SP were dissolved in
chloroform until a homogeneous solution was obtained. For each SP, two
types of blends were prepared; a blend with 30/70 wt.% of SP/PLA and a
blend with 50/50 wt.% of SP/PLA.
After this step, a fixed volume (2.5 ml) of the different solutions where
placed in petri dishes and, in order to obtain the films, the chloroform was
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left to evaporate following two different approaches. Some of the samples
were placed in the oven at 50 oC until all the solvent evaporate or in a fume
hood, at room temperature.
When dried, the flexibility of the obtained films was evaluated and the
samples with the best properties were chosen.
3.2.3 Drug Encapsulation
The films with the most promising properties were selected to encapsulate
acetazolamide in order to obtain a DDS for glaucoma treatment. The encap-
sulation was accomplished by mixing 25 mg of the drug in 25 ml of blends
prepared in the previous step (SP/PLA dissolved in chloroform). Afterwards,
a fixed volume (2.5 ml) of the different solutions with acetazolamide where
placed in petri dishes and the chloroform was evaporated following the same
two different approaches already mentioned. With this process, different
films incorporating acetazolamide were obtained.
In the final step, for encapsulation studies films with acetazolamide were
coated with a solution of polyester/PLA or with a silicone.
In order to monitor the drug release and the efficiency of the coatings,
the films were submerged into 25 ml of PBS and placed in a shaker at 37 oC
and 100 rpm, for two weeks. The amount of drug released over the days was
quantified by UV/Vis spectroscopy, as explained above.
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3.3 Characterization Techniques
3.3.1 Chemical Characterization
In order to obtain detailed information about the chemical structure of the
synthesized polyesters, their monomers and the blends with PLA, a careful
chemical characterization was carried out using different techniques.
Fourier Transform Infrared (FTIR) Spectroscopy
FTIR Spectroscopy is an important technique used to identify and char-
acterize functional groups presented in a sample. For the purpose of this
project, the chemical structure of the synthesized polyesters was confirmed
by Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR).
ATR-FTIR analysis was carried out with a Jasco FT-IR-4200 spectrometer,
equipped with a Golden Gate Single Reflection Diamond ATR. Data collec-
tion was performed with wavelength ranging from 4000 to 500 cm−1, with 4
cm−1 spectral resolution and 64 accumulations. The signals obtained were
represented in spectrum where, the vertical and horizontal axis, correspond
to the transmittance (%) and the wavelength (cm−1), respectively.
Nuclear Magnetic Resonance (NMR) Spectroscopy
NMR Spectroscopy provides information about the structure and chemical
composition of a sample. This technique was applied to analyze the chemical
structure of the synthesized polyesters. Proton nuclear magnetic resonance
(1H NMR) spectroscopy is used to identify the carbon-hydrogen framework.
The analysis was performed in a Bruker Avance III 400 MHz spectrometer,
with a 5 mm TIX triple resonance detection probe. Deuterated tetrahydro-
furan (THF-d8) was used as solvent. Tetramethylsilane (TMS) was used as
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the internal reference.
Size Exclusion Chromatography (SEC)
SEC is a technique currently used to determine the molecular weight distri-
bution of polymers and to obtain Mn (number molecular weight) and Mw
(average molecular weight). In this type of chromatography, the molecules
of a sample are separated based on their size (hydrodynamic volume).
The molecular weight distribution of the samples was determined us-
ing high-performance gel permeation chromatography (HPSEC; Viscotek
TDAmax) with a differential viscometer (DV), right-angle laser-light scatter-
ing (RALLS, Viscotek), low-angle laser-light scattering (LALLS, Viscotek),
and refractive-index (RI) detectors. The column set consisted of one Viscotek
Tguard column (8 µm), one Viscotek T2000 column (6 µm), one Viscotek
T3000 column (6 µm) and one Viscotek LT4000L column (7 µm). Before
the injection, the samples were filtered through a polytetrafluoroethylene
(PTFE) membrane with 0.2 µm pore. The system was calibrated with nar-
row PS standards.
3.3.2 Thermal and mechanical characterization
The thermal and mechanical properties of the different polymers studied in
this work were analyzed by thermogravimetric analysis (TGA), differential
scanning calorimetry (DSC) and by dynamic mechanical thermal analysis
(DMTA).
Thermogravimetric analysis (TGA)
TGA allows the study of the thermal stability of a sample in which the mass
of a sample is monitored as a function of the sample temperature and/or
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time, when the sample is subjected to a specific temperature program. For
the purpose of this project, this technique was used to study the synthesized
polyesters and films of PLA/polyester.
The thermal stability of samples was evaluated by thermogravimetric
analysis (TGA), using a TA Instruments Q500 thermogravimetric analyzer
(thermobalance sensitivity: 0.1 µg). The equipment was calibrated within a
temperature interval ranging from 25 oC to 1000 oC, at a heating rate of 10
oC ·min−1, running tin and leads as melting standards. The samples were
analyzed using open alumina crucibles, in the temperature range 25 oC to
600 oC and at a heating rate of 10 oC ·min−1, under dry nitrogen purge flow
of 100 ml ·min−1.
Differential Scanning Calorimetry (DSC)
DSC is a thermal technique that measures the heat flow involved in ma-
terials transitions as a function of temperature. The sample in study and
the reference sample are heated/cooled simultaneously using two indepen-
dent furnaces. When transitions occur during heating/cooling, the heat flow
versus temperature is registered.
The DSC studies of the polyesters and PLA/polyester films were per-
formed in a TA Instruments Q100 model. The thermal history of the sam-
ples was erased by heating the samples until 110 oC and, then, their thermal
behavior was measured in a temperature range -80 oC to 180 oC, at a heating
rate of 10 oC ·min−1. The whole process took place under a 50 ml ·min−1
flow of dry nitrogen.
Dynamic thermal mechanical analysis (DMTA)
DMTA is a technique that measures the stiffness and damping of materials.
An oscillating load is applied to a sample and its elastic and viscous responses
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are monitored against time, temperature or frequency of oscillation, over a
temperature range. DMTA is currently an extremely popular technique due
to its high precision in the determination of the glass transition temperature
(Tg) of the polymeric materials.
The synthesized polyesters were placed in stainless steel material pockets
and analyzed using a Tritec 2000 DMA, in single cantilever bending geometry.
The tests were carried out from -150 oC to 300 oC, with a standard heating
rate of 5 oC ·min−1, and in multifrequency mode (1 Hz and 10 Hz).
Tensile stress-strain test
In a tensile stress-strain test the mechanical resistance of materials is eval-
uated. The specimen was pulled until fracture, in a short time interval and
constant velocity and an engineering stress-engineering strain diagram (σ−ε)
is obtained.
With the purpose of studying the mechanical properties of the PLA/polyester
films, samples with an average size of 6 × 2 cm were tested. The tests were
performed at room temperature, with a crosshead speed of 10 mm ·min−1
using the Chatillon TCD 1000 equipment. For each film, three measurements
were done.
3.3.3 Morphologic Characterization
Scanning Electron Microscopy (SEM)
SEM is an image formation technique which provides information about mor-
phology / topography of the surface of the material in study. A beam of
electrons interacts with the atoms of the surface of a sample. The secondary
electrons, emitted by these interactions, are used to form an image of the
surface of the material.
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First, the samples were treated in order to become conductive, which was
accomplished by physical vapor deposition of gold particles. Finally, in order
to analyze the surface of PLA/polyester films, a TESCAN VEGA3-SEM
Analytical Scanning Electron Microscopy was used.
Contact Angle (CA)
The determination of the CA where a liquid meets a solid surface gives infor-
mation about wettability of that material, being also an important technique
to calculate the surface energy of a sample. As mentioned by Fo¨rch and co-
workers [37], the CA is defined as the angle at which a liquid/vapor interface
meets the solid surface.
The CA of polyester/PLA films was determined using OCA 20 equipment,
from Dataphysics. To simulate the eye environment, water was the solvent
selected for the measurements. For each test 10 µl of water was dropped, at
a rate of 0.50 µl/s. The tests were performed using the static mode.
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3.4 Drug release quantification
3.4.1 Ultraviolet/Visible (UV/Vis) Spectrophotometry
UV/Vis spectroscopy consists in the study of the interactions between the
light and a sample. When a beam of light crosses a sample or solution, some
of components are absorbed and some are transmitted (Figure 3.2).
Figure 3.2: Illustration of the absorbance process in a spectrophotometer
cuvette.
The ration between the intensity of the incident light (I0) in the sample
and the transmitted light (IT ) is known as transmittance (T) (see Equation
3.1).
T =
IT
I0
(3.1)
The absorbance (A) can also be calculated, being related with the nega-
tive logarithm of transmittance, as represented in Equation 3.2.
A = −log10T (3.2)
According to Beer-Lambert Law, for an ideal solution, there is a linear
relationship between the concentration (c) and the absorbance as long as the
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path length (l) of the cuvette is kept constant. This law can be written as
(see Equation 3.3) :
A = εcl (3.3)
where ε is the absorptivity at a specific wavelength.
In UV/Vis spectroscopy, the choice of the appropriate type of cuvette is
crucial. Quartz cuvettes are probably the best choice due to their wavelength
range and optical qualities. Nevertheless, they are expensive and, being fre-
quently reused, contaminations may occur during the measurements. These
make disposable cuvettes (plastic, UV-grade or glass cuvettes) advantageous
when referring to costs and prevention of contamination. However, the last
ones can only be used at wavelengths above 360 nm. For wavelengths below
300 nm UV-grade cuvettes are used, even though they present significant
absorbance around 240 nm. Below that wavelength only quartz cuvettes can
be used. A standard 10 mm cuvette has a maximum volume of 3.5 ml but,
for limited volume assays, there are available other cuvettes with smaller
volume. [38]
UV/Vis spectroscopy was used to measure the amount of drug released
from different PLA/polyester films over time. A JASCO V-550 spectropho-
tometer with a deuterium and a halogen lamp was used for the purpose of
this study. Two 10 mm UV High Precision Cells made of natural quartz
crystals, with 3.5 ml capacity, from Hellman Analytics, were used during the
whole process.
The first step of the measurements consists in determining the wavelength
at which acetazolamide absorbs. Using as reference a phosphate buffered
saline (PBS) solution (in order to mimic the physiological conditions of the
eye) with pH 7.4, it was determined that the drug absorbed with a maximum
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at 266 nm.
The second step was to prepare a calibration curve with solutions of
known concentration. For which solution, the absorbance was registered
using a PBS solution as reference. Afterward, the calibration curve was ob-
tained by plotting the concentrations and respective absorbance (see Figure
3.3).
Figure 3.3: Example of a calibration curve.
Thus, knowing the absorbance of the samples, their concentrations can
be obtained through the calibration curve.
Finally, the absorbance of samples was measured over time. For each
type of film a reference solution, containing the films but no drug, and three
solutions with films containing acetazolamide were prepared. Two cuvettes
were placed in the spectrophotometer, one containing the reference liquid
and another with the solution with the drug.
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Results and Discussion
4.1 Synthesis and characterization of Satu-
rated Polyesters
As mentioned in 3.2.1, four different saturated polyesters were synthesized for
plasticization of PLA. Saturated polyesters can be obtained by polyconden-
sation of a saturated acid and a glycol. Figures 4.1 to 4.4 show the chemical
structures of the synthesized SPs in this work.
Figure 4.1: Chemical structure of SP1.
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Figure 4.2: Chemical structure of SP2.
Figure 4.3: Chemical structure of SP3.
Figure 4.4: Chemical structure of SP4.
The main objective of the different syntheses was to determine the effect of
the composition of the SP in the plasticization of PLA. To understand this
effect, the chemical characterization of the obtained SPs is essential. The
chemical structure of the synthesized polyesters was analyzed by ATR-FTIR
(Figure 4.5).
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Figure 4.5: ATR-FTIR spectra for SP1, SP2, SP3 and SP4.
As expected, the spectra presented in Figure 4.5 show bands correspond-
ing to the stretching vibration of the carbonyl group of the ester linkage (a)
(1750-1725 cm−1). [39][40][41] The bands in the 1650-1580 cm−1 and 1510-
1450 cm−1 (b) regions are characteristic of the aromatic ring of isophthalic
acid present in SP2 and SP4. In the same polyesters, it was observed a
distinct peak at 725 cm−1 (c), ascribed to the aromatic C-H out-of-plane
bending vibrations.[39] The presence of absorption peaks at ca. 2860 cm−1
(d) can be attributed to the vibrational modes from the CH2 groups. In
all samples, the peaks in the characteristic region 1150-1050 cm−1 (e) can
be attributed to the C-O group. The absence of peaks in the region 3600-
3200 cm−1, ascribed to the hydroxyl group, indicates that all the monomer
reacted. [39] As expected, no bands were observed in this region.
Further insights onto the chemical structure of the SPs were given by 1H
NMR. THF − d8 was used as solvent for the analysis of the samples.
33
Chapter 4
The SP1 spectrum (Figure 4.6) exhibits three distinct peaks at δ = 1.32
ppm (a), 1.59 ppm (b) and, 2.28 ppm (c) which are ascribed to the internal
–CH2 protons of the SeA. As expected, all the SPs present all the three peaks,
proving the incorporation of the SeA in the structure of the polyesters. For
formulations containing isophthalic acid (IPhA), SP2 and SP4, three peaks
at δ = 7.5 ppm (i), 8.2 ppm (h) and 8.63 ppm (j) can also be assigned to the
protons characteristics of the aromatic ring of the acid.
Figure 4.6: 1H NMR of SP1.
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Figure 4.7: 1H NMR of SP2.
Figure 4.8: 1H NMR of SP3.
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Figure 4.9: 1H NMR of SP4.
As can be seen in Figures 4.1 to 4.4, two different diols were selected for
the synthesis of SPs, diethylene glycol (DEG) and 1,6-hexanediol (HEX). In
formulations with DEG, SP1 and SP2, the signals of the –CH2 protons are
presented between 3.6 and 4.5 ppm. On the other hand, the CH2 protons of
the HEX can be identified in the chemical structure of SP3 and SP4. [42] In
SP3 spectrum (Figure 4.8), the internal CH2 protons are located between 1.4
(f) and 1.6 ppm (d) while the peak at 4.0 ppm (e) corresponds to the –CH2
bonded to the ester groups. On the other hand, and due to the presence of
the IPhA, in SP4 spectrum (Figure 4.9) it is also possible to identify –CH2
protons at 1.8 and 4.3 ppm.
From these assignments it is possible to calculate the approximate com-
position of the polyesters comparing with the feed composition as well as
their AV values of the obtained polyesters (Table 4.1).
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Table 4.1: Synthesis conditions of the synthesized SPs from diethylene gly-
col (DEG), sebacic acid (SeA), 1,6-Hexanediol (HEX) and isophthalic acid
(IPhA).
Polyester Composition
Initial Molar
Ratio (%)
Acids/Alcohols
Final Molar
Ratio
AV
(mg KOH/g)
SP1 DEG/SeA 50/50 50/50 24.3
SP2 DEG/SeA/IPhA 50/25/25 35/35/30 26.4
SP3 HEX/SeA 50/50 48/52 21.9
SP4 HEX/SeA/IPhA 50/25/25 30/28/42 28.9
As can be seen in Table 4.1, the molar amount of monomers in the feed
and the final composition of SPs calculated by NMR has some differences.
These differences can be justified by the loss of diols during the polyconden-
sation reaction, by the reaction conditions and by the different reactivity of
the monomers.
The thermal stability of the SPs was studied by termogravimetric analysis
(TGA). Figure 4.10 presents the TGA curves for the different SPs.
37
Chapter 4
Figure 4.10: Thermogravimetric curves of SPs (a) TG and (b) DTG.
The synthesized SPs present a single stage of weight loss (Figure 4.10
(a)), which can be confirmed by the presence of a single peak in the deriva-
tive thermogravimetric (DTG) curve (Figure 4.10 (b)), presenting a similar
thermogravimetric profile. All the studied polyesters are stable until high
temperatures, starting to decompose at approximately 300 oC. However, a
closer look reveals that SP1 is the less stable polyester which is explained by
the absence of an aromatic ring in its structure as well as the chain length of
the glycol. In fact, the HEX presented in the structure of SP3 has a higher
number of carbons in the main chain and, consequently, this polyester has
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higher thermal stability when compared to SP1. On the other hand, poly-
mers with IPhA presented the highest thermal stability. According to Scheirs
[43], IPhA can be used to improve the rigidity of the polymers, proving the
obtained results. As already indicated, and confirmed by the results pre-
sented in Table 4.2, the thermogravimetric profile of the SPs is similar. SP1
has lower values of T5% and T10%, being the less stable of all four polyesters.
By its turn, SP4 has higher T5% and T10% which makes it the more stable of
the synthesized polyesters.
Table 4.2: Characteristic temperatures of the SPs. T5%: temperature cor-
responding to 5% of mass loss; T10%: temperature corresponding to 10% of
mass loss.
Polyester T5% (
oC) T10% (
oC)
SP1 255.67 310.87
SP2 260.58 346.54
SP3 268.39 322.58
SP4 282.49 353.04
The thermal events of the synthesized polyesters were studied by DSC
and DMTA. The thermal history of the samples was erased by heating the
samples until 125 oC. Then, their thermal behavior was measured by cooling
the samples until -80 oC and, finally, they were heated until 200 oC. The heat
flow curve from the cooling cycle (a) and the second heating cycle (b) are
represented in Figure 4.11.
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Figure 4.11: DSC curves of the synthesized SPs obtained at the cooling cycle
(a) and at the second heating cycle (b).
According to Figure 4.11 (b), SP1, SP3 and SP4 have crystalline and
amorphous regions which is proved by the presence of an endothermic peak
matching the melting temperature of the polyesters. On the other hand,
SP2 is an amorphous material proved by the absence of Tm. By its turn, SP4
presents two Tm, which can be explained by two distinct crystalline areas
in the polymer. Finally, SP1 curve holds two endothermic events interposed
by an exothermic event. This type of events, for the specific case of this
polyester, is not described in the literature. It’s important to note that
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DSC analyzes were repeated for both polyesters (SP1 and SP4) in order
to understand if the obtained results were correct. The results of a second
analysis proved to be consistent with the first analysis.
Table 4.3 presents the data obtained by differential scanning calorimetry
for the synthesized polyesters and PLA. SP4 presents two Tm both inferior
to the Tm of SP3. SP1 and SP3 are the simplest polyesters synthesized. As
a consequence of the lack of information concerning the Tm of SP1 it’s not
possible to compare these two polyesters. However, the Tc of SP1 is lower
than the value obtained for SP3 which can be due to the presence of DEG
in its structure.
Table 4.3: DSC of the SPs and PLA (Tc: Crystallization Temperature; Tm:
melting temperature).
Polyester Tc (
oC) Tm(
oC)
SP1 0.00 —–
SP2 —– —–
SP3 41.05 60.86
SP4 16.85 34.57/41.89
PLA —– 175.08
Table 4.4 presents the Tg values obtained from DSC and DMTA for all
synthesized SPs and PLA. The differences observed between the values ob-
tained by these two techniques can be ascribed to differences in the principles
used to determine its value. [39] With exception of SP1, the Tg of the samples
can be obtained by DSC. However, DMTA is a technique with higher preci-
sion in the determination of the glass transition temperature of the polymers.
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Table 4.4: Glass transition temperature obtained from DMTA and DSC.
Polyester
Tg (oC)
Tan δ(max)
DMTA DSC
SP1 -24.7 —— 0.07
SP2 51.9 -38.1 0.02
SP3 -53.0 -39.8 0.07
SP4 -9.2 -14.6 0.05
PLA 77.6 60.4 0.22
SP1 presents lower value of Tg when compared to SP2. This result is
expected due to the absence of an aromatic ring in its structure. On the
other hand, the lowest Tg value was observed for SP3. Indeed, this polyester
has no aromatic ring and has a glycol with longest carbon chain, giving higher
flexibility. As a consequence, lower Tg was expected. Finally, the values of
loss tangent (tan δ) reveal that all synthesized SP have little capacity to
dissipate energy.
As mentioned before, SPs were synthesized to plasticize PLA. The choice
of a plasticizer depends on the desired final properties of the material. For
that, it is important to understand the compatibility between the plasticizer
and the polymer. Chemical structure of the plasticizer (including chemical
composition and molecular weight) is one of the parameters that can affect
the solubility of the plasticizer in the polymer. [31][32] Thus, the synthesized
SPs were studied by SEC in order to determine their molecular weight. All
the samples have a molecular weight inferior to 4000 g.mol−1, which makes
them low molecular weight plasticizers. Another parameter to take into
account is the Tm of the plasticizer. Lower Tm values can lead to increases
solubility of the plasticizer in the material since less energy is required to
fuse with the polymer. Thus, it is expected that SP4 is able to plasticize
PLA more easily that SP3, since it has lower Tm values.
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After synthesis and charactherization of the polyesters, they were used to
form films. These films were characterized in order to understand if plasti-
cization occurred. Finally, the most promissing films were used to study the
drug release of acetazolamide.
4.2 Film formation and characterization
To obtain a plastified film of PLA, it is important to identify the suitable sol-
vent to dissolve this polymer. As mentioned by several authors, PLA is solu-
ble in chloroform and dichloromethane. However, the use of dichloromethane
revealed to be less efficient. In fact, due to its lower boiling temperature
(Tboiling = 39.6
oC) when compared to chloroform (Tboiling = 61.2
oC), the
films prepared with this solvent presented an heterogeneous structure with
some bubbles.
On the other hand, different proportions of SP/PLA (20/80 wt.% , 30/70
wt.% and 50/50 wt.%) were studied for the formation of films. However, as
can be seen in Figure 4.12 (a), the combination of 20/80 wt.% of SP1/PLA
showed to be unable to form a homogenous film by solvent casting. Figure
4.12 (b) shows a 50/50 wt.% SP1/PLA film.
Thus, taking these results into consideration, two types of blends were
prepared; a blend with 30/70 wt.% of SP/PLA and a blend with 50/50 wt.%
of SP/PLA. Table 4.5 shows the composition of each film.
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(a) (b)
Figure 4.12: Film containing 20/80 wt.% of SP/PLA (a) and a film containing
50/50 wt.% of SP/PLA (b).
Table 4.5: Composition of the SP/PLA films obtained in the oven.
Films SP/PLA ratio (%)
SP1 PLA70 O SP1/PLA 30/70
SP1 PLA50 O SP1/PLA 50/50
SP2 PLA70 O SP2/PLA 30/70
SP2 PLA50 O SP2/PLA 50/50
SP3 PLA70 O SP3/PLA 30/70
SP3 PLA50 O SP3/PLA 50/50
SP4 PLA70 O SP4/PLA 30/70
SP4 PLA50 O SP4/PLA 50/50
After the film formation (as explained in 3.2.2) it was possible to under-
stand that SP1 PLA70 O as well as SP2 and SP4 (with both SP contents)
dried in the oven at 50 oC were unable to form films. Nevertheless, SP1
PLA50 O, SP3 PLA70 O and SP3 PLA50 O formed films able to be used for
drug delivery studies.
It is known that a plasticizer should decrease the Tg of PLA and enhance
tensile toughness. [32] In order to understand if SP1 and SP3 were able to
plasticize PLA, the thermal and mechanical properties of the resulting films
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were studied.
The thermal events of the synthesized films, specifically the Tg values,
were studied by DSC. The heat flow curve from the cooling cycle (a) and the
second heating cycle (b) are represented in Figure 4.13.
Figure 4.13: DSC curves of the SP/PLA films obtained at the cooling cycle
(a) and at the second heating cycle (b).
Figure 4.13 (a) shows the crystallization peak for each film. According
to Okamoto [29], PLA has no cristalization peak in the cooling step. On
the other hand, as presented in Table 4.3, SP1 and SP3 have crystalization
peaks at 0 oC and 41.05 oC, respectively. Thus, in the presented films, only
the crystalization of SPs is observed. Figure 4.13 (b) shows the endothermic
peaks associated with the Tm values for the three films, being these values
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close to the Tm value for PLA. Moreover, for the films with SP3, it was also
identified the endothermic peak characteristic of the polyester, at around 61
oC. In addition, the curve of SP1 PLA50 O film presents the two endothermic
events identified in the DSC study of SP1. The DSC analysis was repeated
for this film, which proved to be consistent with first analysis. A similar
profile was found for films left in the fume hood to evaporate the chloroform.
According to Okamoto [29] , it is expected the presence of a crystallization
peak in the heat flow curve of the second heating (Figure 4.13 (b)). How-
ever, this peak is not observed for any film, being ascribed probably due to
the rearrangement of the polymeric chains during cooling, after the thermal
history of the polymer was erased during the first heating.
Table 4.6 presents the data obtained by this thermal analysis.
Table 4.6: DSC of the SP/PLA films (Tc : Crystallization Temperature; Tm
: melting temperature; ∆Hm : fusion enthalpy).
Films Tc (
oC) Tm (
oC) ∆Hm(J · g−1)
SP1 PLA50 O 4.12 173.66 26.31
SP3 PLA70 O 35.30 176.60 22.27
SP3 PLA50 O 33.66 175.76 19.85
The Tm values of the films showed to be similar to each other. The fusion
enthalpy (∆Hm) of the films was determined in order to understand if there
was a variation in the crystallinity of the PLA caused by the incorporation of
SP. When compared to neat PLA(∆Hm = 47.34 J · g−1), the films presented
lower ∆Hm values indicating a decrease of nearly 50% of crystallinity.
In addition to the described thermal events, no other event was detected
in the studied films. Indeed, it was not identified any Tg value by DSC. Thus,
the Tg of each film was determined by DMTA. However, this technique proved
to be ineffective in determining the Tg of the films by tension mode, the
geometry currently applied to analyse this type of samples. Consequently,
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with respect to the plasticization of PLA no conclusion can be drawn based
on the Tg of the films. However, it is important to note that assuming that
the films are plasticized a reduction of Tg is expected.
The mechanical properties of the films prepared in the oven and in the
fume hood were evaluated by a tensile stress-strain test. It is important to
note that the samples used for these tests do not have a standard shape. Con-
sequently, no quantitative analyses were performed. The obtained results for
the SP/PLA films formed in the oven proved to be inconclusive. Therefore,
they are not presented in this work. Figure 4.14 shows the obtained results
for the SP/PLA films formed in the fume hood. The PLA films (without any
SP) were also prepared in order to be used as a reference material.
Figure 4.14: Stress vs strain curves from tensile testing for SP/PLA films
prepared in the fume hood.
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As can be seen in Figure 4.14, all the three blends showed a decrease in
yield strength (σy) when compared to PLA films. However, SP1 PLA50 F
and SP3 PLA50 F show a clear increase in the elongation at break (εb) which
indicates a ductile behaviour with formation of necking. By its turn, SP3
PLA70 F show a brittle behaviour. By the data obtained through the tensile
testing it is possible to observe that the SP1 PLA50 F and SP3 PLA50 F
seem to be plasticized.
Despite being an exact technique to measure the yield strength, elonga-
tion at break and Young modulus of a material, the use of a non-standard
geometry for the tests and the non-homogeneity of the films can lead to erros
in the data obtained.
To understand how water interactes with the surface of the films, the
contact angle (CA) of the films were also studied and the results are presented
in Table 4.7.
Table 4.7: Contact angle of SP/PLA films.
Sample
Evaporation
Process
CA (o) Error (o)
PLA 100% O
Oven
75 3
SP1 PLA50 O 59 3
SP3 PLA70 O 79 2
SP3 PLA50 O 92 2
PLA 100% F
Fume Hood
77 2
SP1 PLA50 F 58 2
SP3 PLA70 F 91 3
SP3 PLA50 F 87 2
The CA for PLA is similar by the films obtained in the oven and in the
fume hood, presenting a partially wetting surface. [37] By their turn, SP1
PLA50 films have a decrease in contact angle when compared to PLA films,
which can indicate that this blend is more prone to suffer degradation due to
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interaction with water. SP3 PLA70 and SP3 PLA50 have an increased CA
when compared to PLA films, which makes them more hydrophobic, and non
wetting. Thus, it is expectable that the drug delivery systems using these
type of films present lower release of the drug in the first days. The CA of
both sides of the films were measured and proved to have identical CA.
4.3 Drug Releasing Tests
To understand the relationship between the concentration of the drug and
the absorbance measured in the spectrophotometer, the calibration curve of
acetazolamide was established. As mentioned in 3.4.1, a full wavelength scan
was run in order to determine the maximum absorbance peak of acetazo-
lamide. The results of such measurement determined that the drug absorbed
with a maximum at 266 nm. Thus, all the measurements performed in this
work were carried out in a fixed wavelength of 266 nm.
To obtain the calibration curve (presented in Figure 4.15), a main solu-
tion was prepared by dissolving acetazolamide in a saline solution, with a
final concentration of 0.06 mg/ml. Different volumes of this main solution
were distributed for different flasks obtaining five different concentrations of
acetazolamide. Table 4.8 present the absorbance obtained in the spectropho-
tometer for each solution.
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Table 4.8: Details of the prepared dissolutions to build the acetazolamide
curve.
Concentration (mg/ml) Absorbance
0.06 0.9114
0.018 0.3890
0.012 0.2393
0.006 0.1316
0.003 0.0756
0.0015 0.0411
Figure 4.15: Calibration curve of acetazolamide, relating the measured ab-
sorbance and the concentration of the solutions.
With the concentrations and respective absorbance (Table 4.8), the cal-
ibration curve for the drug was obtained and is presented in Equation 4.1,
where y is the absorbance and x the concentration:
y = 15.949 · x (4.1)
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4.3.1 Experiment number 1
As indicated above, three films were selected for drug encapsulation: SP1
PLA50 O, SP3 PLA70 O and SP3 PLA50 O. As explained before, 25 mg of
acetazolamide were dissolved in 25 ml of film solution. Afterwards, a fixed
volume (2.5 ml) of the different solutions was placed in petri dishes and, in
order to obtain the final films, the chloroform was left to evaporate in an
oven at 50 oC. Three discs with a diameter of 2 cm were obtained for each
sample, containing 1 mg of acetazolamide each. In addition, as reference, a
film without the drug was also prepared. The four films were next submerged
into 25 ml of PBS and placed in a shaker at 37 oC and 100 rpm. Then, the
drug delivery behavior of the films was studied.
After 4 hours of immersion and in the following days, for a period of 8
days, the absorbance was measured for all samples. Using the calibration
curve (Figure 4.15), the concentration of the drug in PBS solution for each
film was calculated. For each reading, the PBS solution was returned to
the vials until next measurement. The results of the average release for
these three samples are shown in Figure 4.16, where 100% of released drug
corresponds to the total 1 mg of acetazolamide.
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Figure 4.16: Comparison between the acetazolamide releasing profile by SP1
PLA50 O, SP3 PLA70 O and SP3 PLA50 O films over the course of 8 days.
In all three samples (with drug) it is clear that a burst release takes place
during the first 4 hours of immersion. With a total release of the drug in
the first 24 hours, SP1 PLA50 O films were eliminated of this study. On the
other hand, SP3 PLA70 O and SP3 PLA50 O showed similar drug release
during the first 8 days. After this period, SP3 PLA70 O released 38.6±17.8%
of the drug whereas SP3 PLA50 O released 48.9±12.6%. It is clear that SP3
PLA70 O films showed lower release when compared to SP3 PLA50 O films,
but taking into account the associated errors, this difference is not significant.
The release profile of these two films may also indicate that acetazolamide
is stable inside and outside of the films, since after a period of 5 days the
release of the drug tends to stabilize. It is also important to note that after
this study, the films showed no signs of degradation.
To evaluate the surface properties of the films, SEM imaging was per-
formed. Figure 4.17a shows the surface of a SP1 PLA50 O film. The het-
erogeneity of the surface can be due to phase separation of the PLA and the
plasticizer. Figure 4.17b shows an image of the cross section of the same film,
which allows to understand that the film is porous. The surface morphology
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of the films is also visible. Thus, the irregularities observed in the surface
and the porosity in the material support the high releasing rates obtained
for this type of films.
(a) (b)
Figure 4.17: SEM image of (a) the surface (with a magnification of 100X)
and (b) the cross section (with a magnification of 500X) of SP1 PLA50 O
films.
By their turn, SP3 PLA70 O and SP3 PLA50 O films present similar
surfaces, as can be seen in Figure 4.18a and Figure 4.19a, respectively. Both
films present a morphology similar to neat PLA (see Appendix A), but they
present phase separation. The spherical structures in their surface are smaller
than the ones in the surface of SP1 PLA50 O films. Also, their homogeneity
when compared to the SP1 PLA50 O films can explain the better results of
drug release obtained by these films. When analyzing the cross section of
SP3 PLA70 O (Figure 4.18b) and SP3 PLA50 O (Figure 4.19b) it is possible
to understand that the films are porous, as seen for SP1 PLA50 O films
(Figure 4.17b).
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(a) (b)
Figure 4.18: SEM image of (a) the surface (with a magnification of 100X)
and (b) the cross section (with a magnification of 500X) of SP3 PLA70 O
films.
(a) (b)
Figure 4.19: SEM image of (a) the surface (with a magnification of 100X)
and (b) the cross section (with a magnification of 637X) of SP3 PLA50 O
films.
4.3.2 Experiment number 2
In a second experiment, the films SP3 PLA70 O and SP3 PLA50 O were
coated with the same polyester solution used in their preparation (SP3/PLA)
in order to decrease their release rates. Three films containing acetazolamide
were coated using a paint-brush and placed, as before, in a vial with 25 ml of
PBS. Being the reference, one film without any drug also coated. Two types
of measurements were made: one in which the solution of PBS was returned
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to the vial after the reading, as done for the first experiment, and one in
which the solution of the vial was replaced by new PBS each time a reading
was performed.
Figure 4.20 shows the releasing profiles of SP3 PLA70 O and SP3 PLA50
O coated films when the PBS solution is kept the same. The absorbance
was measured 4 hours after the immersion and in the following days, for two
weeks.
Figure 4.20: Comparison between the non-cumulative acetazolamide releas-
ing profile by SP3 PLA70 O and SP3 PLA50 O coated films over the course
of 14 days.
The presence of the coating proved to be effective in decreasing the
prompt release during the first 4 hours of immersion. SP3 PLA70 O films
showed a decrease in its release from 27.8 ± 5.3% to 6.8 ± 3.0% in the first
4 hours, being that for sample SP3 PLA50 O the release decreased from
27.8± 8.1% to 8.5± 4.5%. Unlike the results of the first experiment, where
SP3 PLA70 O showed a lower drug release than SP3 PLA50 O, in the second
experiment SP3 PLA50 O shown lower drug release when compared to SP3
PLA70 O after 24 hours.
The coating proved its efficiency in decreasing the release of acetazolamide
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from SP3 PLA50 O films. After 8 days, SP3 PLA50 O coated films have
released 31.8 ± 13.6% of its drug content when compared to 48.9 ± 12.6%
released by SP3 PLA50 O films without coating. The final values of drug
release after 14 days were 50.6 ± 16.7% for SP3 PLA70 coated films and
38.4± 16.1% for SP3 PLA50 coated films.
In Figure 4.21 it is presented the SEM image of the SP3 PLA70 O film
coated with its main solution. It is clear that the coating was not evenly dis-
tributed across the film, exposing some areas of the film. These observations
confirm the release profile obtained for SP3 PLA70 coated films. During the
coating, the films showed a tendency to dissolve due to the presence of the
solution with chloroform. The change in the surface of the coated films can
be due to the evaporation of chloroform of the solution used for coating.
(a) (b)
Figure 4.21: SEM image of the surface SP3 PLA70 O film coated with its
main solution with a magnification of 100X (a) and with a magnification of
1.000X (b).
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SEM images of the SP3 PLA50 O film coated with its main solution are
presented in Figure 4.22. The coating seems to be more evenly distributed
through the surface of the film when compared to SP3 PLA70 O coated
films. This can explain the lower releasing rates associated with SP3 PLA50
O coated films when compared to SP3 PLA70 O coated films.
(a) (b)
Figure 4.22: SEM image of (a) the surface (with a magnification of 6000X)
and (b) the cross section (with a magnification of 6100X) of SP3 PLA50 O
coated films.
On the other hand, Figure 4.23 shows the releasing profiles of SP3 PLA70
O and SP3 PLA50 O coated films when the surrounding solution was replaced
by PBS solution each time a reading was performed. Thus, the amount of
acetazolamide released in each reading is added to the total amount that was
released until that moment, becoming cumulative results.
The absorbance was measured 4, 16 and 18 hours after the immersion and
in the following days, for two weeks. An increased number of measurements
was made in the first hours of release in order to understand if by replacing
the surrounding medium an intense burst in drug release was observed.
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Figure 4.23: Comparison between the cumulative acetazolamide releasing
profile by SP3 PLA70 O and SP3 PLA50 O coated films over the course of
13 days.
SP3 PLA70 O coated films show lower drug release over two weeks when
compared to SP3 PLA50 O coated films. However, the errors associated with
the readings from SP3 PLA50 O coated samples were high, which can be due
to errors in the experimental methodology and irregular coating of the films.
Similar to the previous experiment, the coating has proved to be efficient
in decreasing the first 4 hours prompt release. The values after 4 hours were
10.3±2.4% for SP3 PLA70 O coated samples and 16.1±2.7% for SP3 PLA50
O coated samples. After 13 days, the total release for SP3 PLA70 O coated
samples was 32.6±5.9% and 54.8±22.0% for SP3 PLA50 O coated samples.
4.3.3 Experiment number 3
A third experiment was performed in order to understand the changes in
drug release when the films were left in the fume hood to evaporate the
chloroform. The three solutions studied in the first experiment were used
to form films. After all the chloroform has evaporated, the discs with film
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were cut and coated with their main solutions. Figure 4.24 shows the release
results for the three films.
Figure 4.24: Comparison between the cumulative acetazolamide releasing
profile by SP1 PLA50 F, SP3 PLA70 F and SP3 PLA50 F coated films over
the course of 14 days.
As seen in the first experiment, SP3 PLA70 F is a promissing formulation
to develop drug delivery systems in order to release acetazolamide over time.
Besides its total released drug after 14 days was only 10.2± 4.6%, the initial
burst observed in other formulation it’s not present for SP3 PLA70 F coated
films (Figure 4.24). Since chloroform evaporated slowly, when compared to
the films obtained in the oven at 50 oC, the polymeric chain had time to
form an organized polymer, which can influence the releasing properties of
the final material. Figure 4.25 shows the three different films obtained in
the fume hood, before being coated. It is visible that all the films present
a porous surface but the phase separation present in the films obtained in
the oven (Figure 4.17 to 4.19) is not observed, which can indicate a better
plasticization of PLA.
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Figure 4.25: SEM images of SP1 PLA50 (a), SP3 PLA70 (b) and SP3 PLA50
(c) films formed in the fume hood with a magnification of 100X.
On the other hand, SP1 PLA50 F and SP3 PLA50 F coated films showed
a fairly similar behavior over 14 days. Both samples showed a brust release
in the first 4 hours, being that 24.3 ± 0.6% of the drug was release to the
saline solution by SP1 PLA50 films and 23.4 ± 14.7% by SP3 PLA50 films.
After 14 days, the total released values were 103.0 ± 11.0% for SP1 PLA50
coated samples and 97.4 ± 9.6% for SP3 PLA50 F coated samples. Ideally,
a drug delivery system should be capable of release drugs for long periods of
time (months), consequently these two films show no promising results for
this application.
With the purpose to overcome this problem, a new coating was tested.
The coating was performed by dip-coating technique. The films were sub-
merged in a 30/70 wt. % n-butyl-acetate/silicone solution.
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Figure 4.26: Comparison between the cumulative acetazolamide releasing
profile by SP1 PLA50 F, SP3 PLA70 F and SP3 PLA50 F films with silicone
coating over the course of 14 days.
The silicone coating proved its efficiency in decreasing the drug release
after 4 hours of immersion (Figure 4.26) and, for SP1 PLA50 F and SP3
PLA50 F samples, it proved to be more effective than the previous coating
in decreasing the release of the drug. The releasing profiles for each film can
be found attached to this work (See Appendix B).
After 14 days, the total release of drug for SP1 PLA50 F sample was
45.9 ± 10.4% and for SP3 PLA70 F sample it was 13.0 ± 10.6%. However,
observing the results of the release values from SP3 PLA50 F it is possible
to understand that these particular films have values close to 0. In order to
understand if acetazolamide was encapsulated inside the films, they were cut
and placed in a PBS solution for 48 hours. Yet, no increase in the absorbance
was registered. Thus, drug release from SP3 PLA50 F coated films must be
assessed in the future.
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The efficiency of the silicone in coating the films was evaluated by SEM.
Figure 4.27 to 4.29 show SP1 PLA50 F, SP3 PLA70 F and SP3 PLA50 F
films, respectively. It is visible that the silicone was more efficient in coating
SP3 PLA70 F and SP3 PLA50 F films, respectively (Figure 4.28 and Figure
4.29). These observations are in line with the releasing profiles of each coated
film.
(a) (b)
Figure 4.27: SEM image of the surface SP1 PLA50 F film coated with silicone
with a magnification of 100X (a) and with a magnification of 1.000X (b).
(a) (b)
Figure 4.28: SEM image of the surface SP3 PLA70 F film coated with silicone
with a magnification of 100X (a) and with a magnification of 1.230X (b).
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(a) (b)
Figure 4.29: SEM image of the surface SP3 PLA50 F film coated with silicone
with a magnification of 100X (a) and with a magnification of 283X (b).
In a final analysis of the data collected through the different experiments,
a comparison between the films prepared in the oven at 50 oC and the ones
prepared in the fume hood at room temperature (the films were formed
between June and November 2015) was carried out. It is important to note
that the room temperature varied depending on the time of the year which
can have an impact in the final properties of the obtained films.
Figure 4.30 compares SP3 PLA70 coated films left in the oven and in the
fume hood to evaporate the chloroform.
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Figure 4.30: Comparison between the cumulative acetazolamide releasing
profile by SP3 PLA70 films prepared in the oven and in the fume hood over
the course of 14 days.
By comparing the release between the films prepared by the two methods,
it is visible that the film prepared in the fume hood shows a lower release
than films prepared in the oven (Figure 4.30). This can be attributed to the
arrangement of the polymeric chains, as mentioned before.
64
Chapter 4
On the other hand, Figure 4.31 shows the differences between the SP3
PLA50 coated films. Contrary to SP3 PLA70 coated films, the films prepared
in the oven present a lower release of acetazolamide over time.
Figure 4.31: Comparison between the cumulative acetazolamide releasing
profile by SP3 PLA50 films prepared in the oven and in the fume hood over
the course of 14 days.
Thus, SP3 PLA70 films seem to be the most promising films to release
drug in a controlled manner since they require smaller amounts of plasticizer
when compared to the other two films, show improved drug release when
coated and when the chloroform is evaporated in the fume hood, at room
temperature.
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Conclusions and Future Work
5.1 Conclusions
Concerning the present work, saturated polyesters (SP) were synthesized and
characterized in order to plasticize poly(lactic acid) (PLA). The obtained
materials were studied as drug delivery systems for acetazolamide.
Four SP were successfully obtained, two aliphatic polyesters (SP1 and
SP3) and two aromatic polyesters (SP2 and SP4), by polycondensation of
saturated acids and a diol. Different proportions of the synthesized polyesters
were combined with PLA and, using the solvent casting process, different
films were obtained. When the chloroform solution of the polymers was
evaporated in an oven, all the polyesters showed to be able to form films with
PLA. However, only SP1 and SP3 polyesters showed to be able to form films
with the PLA with mechanical properties suitable for drug release systems.
The films with improved properties (SP1 PLA50 O, SP3 PLA70 O and SP3
PLA50 O) were studied by DSC and DMTA in order to determine the Tg
value of each film. Both techniques proved to be ineffective in determining
this transition. However, assuming that the films are plasticized, a reduction
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of Tg is expected. The mechanical properties of the films were evaluated
by a tensile stress-strain test. This test proved to be inconclusive for the
films obtained in the oven. At the same time, and in a comparative analysis,
the same drying process was performed at room temperature, in order to
evaluate the impact of slow evaporation of chloroform in the final properties
of the developed materials. Through tensile testing, SP1 PLA50 F and SP3
PLA50 F showed an increased elongation at break.
After characterization, the films were studied by their ability to release
acetazolamide. All the films showed a burst release in the first 4 hours. Thus,
in order to solve this problem, the films were coated with the polymer solution
(SP PLA) or with a silicon based material. The subsequently acetazolamide
release studies were performed. The SP3 PLA70 films obtained in the oven
and in the fume hood, PLA film with polyester constituted by sebacic acid
and 1,6-hexanediol, proved to be the most promising film in what concerns
the drug release profiles. Both coatings proved to be effective in lowering
drug release.
5.2 Future Work
This work was focused primarily in the synthesis and characterization of
saturated polyesters in order to plasticize PLA. As mentioned above, the
polyesters were successfully synthesized and characterized by FTIR, 1H NMR,
TGA and SEC. However, in DSC analysis, it was not possible to separate the
thermal events of SP1 and SP4. In order to overcome this limitation, the use
of modulated DSC is presented as a solution. It is expected that, using this
technique, the identification of the endothermic peak corresponding to the Tm
of the polyester will be possible. In addition, in order to remove the thermal
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history of the sample, the first heating step should be performed in temper-
ature range from -80 to 200 oC. Thus, it will be possible to understand if the
first cycles were responsible for the reorganization of the polymeric chains
and, consequently, for the absence of the cold crystallization peak in second
heating cycle.
It is also noted that, the DSC technique proved to be inefficient in de-
termining the Tg value of the SP/PLA films. The Tg value was determined
by DMTA analysis. However, this technique also proved to be inefficient in
determining the Tg of the films by tension mode. As mentioned, the Tg value
is an important reference of plasticization. Thus, in future work, films with
appropriate geometry and thickness should be formed in order to carry out
the DMTA analysis.
Another important analysis for plasticized films is the tensile testing. In
order to obtain conclusive information from the stress-strain curves of the
films it is important to obtain standard samples for the analyses. This can
be achieved by injection molding of the films.
Furthermore, the use of other plasticizers should be taken into account.
Polyester containing phthalic acid, as an example, and a new method to form
the films may prove useful in order to improve PLA properties.
The promising results obtained to this point can be used to encapsulate
other drugs. Additionally, cytotoxicity of the films and coating should be
evaluated, as well as, the degradation behavior of the former.
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Appendix A
SEM image of the surface of a
PLA film.
Figure A.1: SEM image of the surface of a PLA film with a magnification of
100X.
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Appendix B
Drug Releasing Tests
Figure B.1: Comparison between the acetazolamide releasing profile by SP1
PLA50 F films with coating and with a silicone solution over the course of
14 days.
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Figure B.2: Comparison between the acetazolamide releasing profile by SP3
PLA70 F films with coating and with a silicone solution over the course of
14 days.
Figure B.3: Comparison between the acetazolamide releasing profile by SP3
PLA50 F films coated with film solution and with a silicone solution over the
course of 14 days.
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